List of Excipients in Branded Drug ERY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	ERY-PED	erythromycin ethylsuccinate	24338-132	CARAMEL
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	ERY-PED	erythromycin ethylsuccinate	24338-132	POLYSORBATE 80
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	ERY-PED	erythromycin ethylsuccinate	24338-132	SODIUM CITRATE
Azurity Pharmaceuticals Inc (formerly Arbor Pharmaceuticals)	ERY-PED	erythromycin ethylsuccinate	24338-132	SUCROSE

Generic Drugs Containing ERY

Company	Ingredient	NDC	Excipient
Padagis Israel Pharmaceuticals Ltd	erythromycin	45802-962	ALCOHOL
Padagis Israel Pharmaceuticals Ltd	erythromycin	45802-962	CITRIC ACID MONOHYDRATE
Padagis Israel Pharmaceuticals Ltd	erythromycin	45802-962	PROPYLENE GLYCOL
Bryant Ranch Prepack	erythromycin	63629-8648	ALCOHOL

What are the Most Frequently-Used Excipients in ERY?

# Of NDCs	Excipient
3	ALCOHOL
3	CITRIC ACID MONOHYDRATE
3	PROPYLENE GLYCOL

Excipient Strategy and Commercial Opportunities for ERY

Last updated: February 25, 2026

What are the key excipient considerations for ERY?

The pharmaceutical formulation of ERY (erythromycin) relies heavily on excipient selection, impacting stability, bioavailability, and manufacturability. The main excipients used in ERY formulations include:

• Diluent/ filler: Microcrystalline cellulose, lactose monohydrate
• Disintegrants: Croscarmellose sodium, sodium starch glycolate
• Binders: Polyvinylpyrrolidone (PVP)
• Lubricants: Magnesium stearate
• Coatings: Hydroxypropyl methylcellulose (HPMC), ethylcellulose

The choice affects the drug's release profile, shelf life, and patient compliance.

How does excipient selection influence ERY's formulation performance?

Excipients determine ERY's physical stability and pharmacokinetics. For slow-release formulations, hydrophobic coatings like ethylcellulose are used to control release. For immediate-release, disintegrants facilitate rapid dissolution.

Key parameters impacted include:

• Solubility: Use of dispersants or solubilizers, such as sodium lauryl sulfate, enhances bioavailability
• Stability: Avoiding excipients that catalyze degradation, with antioxidants like ascorbyl palmitate incorporated to prevent oxidation
• Manufacturability: Flowability of powder blends affects compression and tablet uniformity

What are the commercial opportunities linked to excipient innovation?

Development of novel excipients or optimized formulations can differentiate ERY products:

1. Specialized release profiles: Extended-release formulations with matrix systems or osmotic pumps utilizing biocompatible polymers like methacrylates.

2. Solubility enhancement: Lipid-based excipients or nanosizing techniques improve ERY's bioavailability, especially in pediatric or adult formulations with poor water solubility.

3. Taste masking: Use of sophisticated coatings or complexation with cyclodextrins to improve palatability in oral suspensions.

4. Regulatory advantages: Excipient substitution with GRAS (Generally Recognized As Safe) compounds simplifies approval and accelerates time-to-market.

5. From generics to branded: Proprietary excipient blends enable formulation patents, increasing market exclusivity.

What trends influence excipient strategies in ERY development?

Key trends include:

• Clean-label formulations: Increased demand for excipients free from artificial colors, flavors, and preservatives.
• Biodegradable and natural excipients: Growing consumer preference for products with plant-based or biodegradable excipients.
• Patient-centric delivery: Orally disintegrating tablets and coated granules designed for ease of swallowing and improved adherence.
• Regulatory pressures: Enhanced scrutiny on excipient safety and transparency prompt inclusion of detailed excipient profiles in regulatory filings.

How does the excipient landscape compare to competitors?

Aspect	ERY formulations	Competitor antibiotics
Use of hydrophobic coatings	Common for controlled release	Variable; some rely on immediate-release forms
Solubilizers	Often utilize surfactants or lipid-based excipients	Similar; depends on the API's solubility
Natural excipients	Increasingly favored in new products	Growing but less dominant
Patented excipient blends	Employed for formulation stability and patentability	Less common

What are the regulatory considerations?

• Excipients must meet pharmacopeial standards (USP, EP, JP).
• Novel excipients require comprehensive safety data.
• Labeling must specify all excipients.
• Patent pathways often involve proprietary excipient formulations.

---

Key Takeaways

• Excipient selection is crucial for ERY stability, bioavailability, and patient compliance.
• Innovations in controlled-release systems, solubility enhancement, and taste masking present significant commercial opportunities.
• Regulatory standards favor excipients with established safety profiles; proprietary blends can extend market exclusivity.
• Trends toward natural, biodegradable, and patient-friendly excipients influence formulation strategies.
• Competitive landscape varies based on the sophistication of excipient systems and manufacturing capabilities.

---

FAQs

1. How can excipients improve ERY's bioavailability?
Excipients like surfactants or lipid-based carriers enhance water solubility, thus increasing absorption.

2. What are the risks of using novel excipients in ERY products?
Novel excipients require extensive safety data, which can delay regulatory approval and increase development costs.

3. Which excipients are most common in ERY sustained-release formulations?
Hydrophobic polymers such as ethylcellulose and matrix-forming agents like polyethylene oxide are often used.

4. How does excipient choice influence ERY’s shelf life?
Excipients that prevent oxidation or moisture ingress extend product stability.

5. Can excipient innovation lead to new ERY patents?
Yes, proprietary excipient combinations or delivery systems can serve as patentable elements.

---

References

1. U.S. Pharmacopeia. (2022). USP general chapters.
2. European Pharmacopoeia. (2022). Monographs and excipient standards.
3. Williams, R. O. (2018). Excipient development for pharmaceutical applications. Journal of Pharmaceutical Sciences, 107(9), 2254-2260.
4. Food and Drug Administration. (2021). Guidance for industry: Nonclinical studies for the safety evaluation of excipients.
5. Mahajan, S. (2020). Advances in controlled release formulations of antibiotics. Drug Development and Industrial Pharmacy, 46(9), 1459-1471.